Major depressive disorder (MDD) remains a leading cause of disability, and many patients need treatments that work differently—or faster—than traditional monoamine-based antidepressants. Auvelity (dextromethorphan 45 mg / bupropion 105 mg extended-release) is an oral medication approved by the FDA in August 2022 for the treatment of MDD in adults. It is the first approved oral antidepressant whose primary mechanism involves glutamatergic modulation rather than solely targeting serotonin, norepinephrine, or dopamine reuptake.
How Auvelity Works
Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist that modulates glutamatergic signaling. Bupropion serves two roles: it inhibits CYP2D6, substantially increasing and prolonging dextromethorphan plasma levels, and it contributes its own norepinephrine-dopamine reuptake inhibition. The exact antidepressant mechanism remains unclear, but the combination produces dual effects on glutamatergic and monoaminergic pathways. The fixed-dose extended-release tablet is taken once daily for three days, then twice daily (at least eight hours apart).
Clinical Evidence
Efficacy is supported by two key randomized, double-blind trials.
In the Phase 3 GEMINI trial (NCT04019704), 327 adults with moderate-to-severe MDD were randomized to Auvelity or placebo for six weeks. The primary endpoint—change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to Week 6—showed a least-squares mean change of −15.9 points with Auvelity versus −12.0 (or −12.1 in label data) with placebo (least-squares mean difference approximately −3.9; 95% CI −6.4 to −1.4; P = .002). Statistically significant separation appeared as early as Week 1. At Week 6, remission (MADRS ≤ 10) was achieved by 39.5% of Auvelity-treated patients versus 17.3% on placebo, and response (≥50% MADRS improvement) by 54% versus 34%.
The Phase 2 ASCEND trial compared Auvelity with the same dose of bupropion sustained-release alone. Auvelity produced a greater overall MADRS improvement (−13.7 vs −8.8; P < .001), confirming that the dextromethorphan component contributes meaningfully beyond bupropion. Remission rates were also higher with the combination.
An open-label Phase 3 study (COMET) of up to 12 months suggested that symptom improvements observed in short-term trials can be sustained, with response and remission rates remaining high among those who continued treatment; however, this was not a controlled trial.
Safety and Practical Considerations
In the GEMINI trial, the most common adverse reactions (≥5% and more than twice placebo) included dizziness (16%), headache (8%), diarrhea (7%), somnolence (7%), dry mouth (6%), sexual dysfunction (6%), and hyperhidrosis (5%). Discontinuation due to adverse events was relatively low (approximately 4–6%). The medication carries the standard antidepressant boxed warning for increased risk of suicidal thoughts and behaviors in young adults. Contraindications include seizure disorders, current or prior diagnosis of bulimia or anorexia nervosa, and concurrent use of MAOIs or other bupropion- or dextromethorphan-containing products. Dose adjustments are required for moderate renal impairment, CYP2D6 poor metabolizers, and strong CYP2D6 inhibitors. Blood pressure should be monitored, and patients should be screened for bipolar disorder before initiation.
Clinical Role
Auvelity offers a mechanistically distinct oral option with evidence of relatively rapid onset (separation from placebo within the first one to two weeks in controlled trials). It may be considered for adults with MDD who have not responded adequately to traditional antidepressants, prefer an oral regimen, or seek a different side-effect profile. It is not approved for pediatric use and is not indicated as monotherapy for treatment-resistant depression in the same way as some interventional treatments. As with all antidepressants, individual response varies, and decisions should be individualized based on patient history, comorbidities, and shared decision-making.
References
- Auvelity prescribing information. Axsome Therapeutics.
- Tabuteau H, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022.
- O’Gorman C, et al. Efficacy and safety of AXS-05 in major depressive disorder: results from the ASCEND trial. Am J Psychiatry. 2022.
- Axsome Therapeutics COMET long-term open-label data.
This information is for educational purposes and does not constitute medical advice. Patients should consult a qualified clinician before starting or changing any medication.